Rainbow Coral Corp (RBCC) 1.5000 $RBCC RBCC Nears Major

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Rainbow Coral Corp (RBCC) 1.5000 $RBCC

RBCC Nears Major Agreement to Distribute Naltrexone in Canada
Business Wire - Thu Jul 09, 4:00AM CDT
Biotech company Rainbow Coral Corp. (RBCC) is drawing closer to a milestone agreement with a partner company to distribute Naltrexone - an important prescription drug used in treatment of alcohol and opiate addiction - in Canada. When reached and implemented, the agreement will open a crucial new revenue stream for RBCC as the FDA-approved drug's previous success has resulted in increased demand for effective new Naltrexone treatments from a wide spectrum of patients.

RBCC Explores New Pharmaceutical Compounding Opportunities in Booming Personalized Medicine Industry
Business Wire - Tue Jun 02, 4:00AM CDT
As Rainbow Coral Corp. (OTCBB:RBCC) works to diversify its rapidly growing biotech business, the company is exploring new opportunities to provide innovative new products and services to the pharmaceutical compounding industry.
ABT: 49.93 (+0.74), BIIB: 388.23 (-11.06), VRX: 232.32 (+8.93)

RBCC Aggressively Pursuing Personalized Medicine Opportunities in Canada
Business Wire - Tue May 05, 4:00AM CDT
Rainbow Coral Corp. (RBCC) is taking full advantage of more research-friendly regulations north of the border to target new personalized medicine opportunities in Canada. These opportunities include marketing cutting-edge treatments utilizing adult stem cells and the reprogramming of a patient's own existing cells to combat a variety of diseases, such as multiple sclerosis, ALS (Lou Gehrig's disease) and Parkinson's.

RBCC Targets Regenerative Medicine Leader to Build Out Partner Portfolio
Business Wire - Mon Apr 27, 4:00AM CDT
Following a series of productive meetings last week, biotech innovator Rainbow Coral Corp. (OTCBB: RBCC) targeted an emerging leader in the field of regenerative medicine for addition to its growing partner portfolio.

RBCC Weighs Opportunities Following Successful Events Schedule
Business Wire - Mon Mar 23, 4:00AM CDT
Following several successful conferences, events, and cross-country meetings, Rainbow Coral Corp. (OTCBB: RBCC) is sizing up potential investment and joint venture partners to expand its portfolio.

RBCC Joint Venture Partner n3D to Present Latest 3D Bioprinting Research in Washington, D.C.
Business Wire - Tue Feb 10, 4:00AM CST
Rainbow Coral Corp.'s (OTCBB:RBCC) 3D bioprinting joint venture partner Nano3D Biosciences (n3D) will present a new abstract detailing the latest breakthroughs made using its technology in Washington, D.C. on Wednesday at the 4th annual Society for Laboratory Automation and Screening Conference and Exhibition (SLAS2015).
ABT: 49.93 (+0.74), BIIB: 388.23 (-11.06), AMGN: 154.10 (+2.79)

RBCC and n3D Pursue New Partnership Opportunities After Highly Successful 3D Bioprinting Exhibit at Biotech Showcase 2015
Business Wire - Thu Feb 05, 4:00AM CST
Rainbow Coral Corp. (OTCBB:RBCC) and Nano3D Biosciences (n3D) are lining up new 3D bioprinting opportunities and potential partnerships following a highly successful product exhibition last month at Biotech Showcase 2015 in San Francisco.
ABT: 49.93 (+0.74), BIIB: 388.23 (-11.06), AMGN: 154.10 (+2.79)

3D Bioprinting Pioneers RBCC and n3D Biosciences Network With Top Biotechnology Investors This Week at Biotech Showcase 2015 in San Francisco
Business Wire - Tue Jan 13, 4:00AM CST
Rainbow Coral Corp. (OTCBB: RBCC) executive leadership will preview the latest innovations and network with top biotechnology investors this week at Biotech Showcase 2015 in San Francisco, where the company's joint venture partner, Nano3D Biosciences (n3D) will exhibit the revolutionary Bio-Assembler device.
ABT: 49.93 (+0.74), BIIB: 388.23 (-11.06), AMGN: 154.10 (+2.79)

3D Bioprinting Technology Developed by RBCC Partner n3D Biosciences Helps Researchers Create a Better In Vitro Breast Cancer Model
Business Wire - Mon Nov 03, 4:30AM CST
A Texas Medical Center research team has made a stunning breakthrough in breast cancer research using revolutionary 3D bioprinting technology being marketed and developed by Nano3D Biosciences (n3D), a joint venture partner of Rainbow Coral Corp. (OTCBB:RBCC).
ABT: 49.93 (+0.74), BIIB: 388.23 (-11.06), AMGN: 154.10 (+2.79)

RBCC Explores Novel Uses for New Naltrexone Delivery Protocols
Business Wire - Thu Sep 04, 4:00AM CDT
From chronic pain to obesity, new research suggests that there are practically no limits to the number of illnesses that the prescription drug Naltrexone can treat. Biotech company Rainbow Coral Corp. (OTCBB:RBCC) is working to make Naltrexone more effective than ever before.
ABT: 49.93 (+0.74), BIIB: 388.23 (-11.06), VRX: 232.32 (+8.93), BMY: 69.27 (+1.38)

RBCC 3D Bioprinting Partner Awarded Prestigious Grant
Business Wire - Thu Jul 31, 5:54AM CDT
The joint venture of Rainbow Coral Corp. (OTCBB: RBCC) and Nano3D Biosciences (n3D), moved significantly closer to its funding goals this week thanks to a prestigious research grant from the National Institutes of Health.
ABT: 49.93 (+0.74), AMGN: 154.10 (+2.79)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 399

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 448

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 0

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

O-I Glass Announces Participation in Citi’s 2025 Conference

Updated Category News Views 208

O-I Glass Participation in the 2025 Basic Materials Conference PERRYSBURG, Ohio — O-I Glass, Inc., known for its commitment to creating exceptional glass products, is set to participate in the upcoming Citi’s 2025 Basic Materials Conference. This significant event will take place on a Wednesday in December, and features notable presentations from O-I's leadership....

Continue Reading
Osmium Partners Proposes Strategic Plan for Articore Growth

Updated Category News Views 104

Osmium Partners Proposes a Four-Step Plan for Articore Osmium Partners has recently made headlines with their proposal for Articore, aiming to elevate shareholder value through a methodical four-step approach. This initiative is driven by Osmium's belief that Articore's current management strategy lacks direction and has resulted in missed opportunities for growth and...

Continue Reading
Amplify Energy Set to Shine at EnerCom Denver Conference 2025

Updated Category News Views 135

Amplify Energy’s Participation in EnerCom Denver Conference Amplify Energy Corp. is gearing up to participate in the renowned annual EnerCom Denver Conference in 2025. This event, known for bringing together leading experts and investors in the energy sector, offers Amplify a prime platform to showcase its strategic initiatives and growth potential. Focus on Investor...

Continue Reading
Safe Life Expands CPR Training and AED Services through Acquisition

Updated Category News Views 197

Safe Life Strengthens National Coverage for Life-Saving Training Safe Life has made a significant move by acquiring HeartCert, a company known for its specialization in automated external defibrillators (AEDs) and CPR training. This acquisition allows Safe Life to broaden its reach into the Midwest, enhancing its commitment to providing life-saving training and equipment...

Continue Reading
Express Scripts Challenges FTC's Drug Pricing Conclusions

Updated Category News Views 106

Express Scripts Files Lawsuit Against the FTC Express Scripts, a major player in the pharmacy benefit manager sector, has recently taken legal action against the U.S. Federal Trade Commission (FTC). This lawsuit stems from a report that criticizes the role of pharmacy benefit managers in the pricing of medications. Express Scripts contends that the report's conclusions...

Continue Reading